JP2021523744A5 - - Google Patents

Info

Publication number
JP2021523744A5
JP2021523744A5 JP2021514483A JP2021514483A JP2021523744A5 JP 2021523744 A5 JP2021523744 A5 JP 2021523744A5 JP 2021514483 A JP2021514483 A JP 2021514483A JP 2021514483 A JP2021514483 A JP 2021514483A JP 2021523744 A5 JP2021523744 A5 JP 2021523744A5
Authority
JP
Japan
Prior art keywords
signature
expression levels
stroke
biomarkers
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514483A
Other languages
English (en)
Japanese (ja)
Other versions
JP7463351B2 (ja
JP2021523744A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/062653 external-priority patent/WO2019219831A1/en
Publication of JP2021523744A publication Critical patent/JP2021523744A/ja
Publication of JP2021523744A5 publication Critical patent/JP2021523744A5/ja
Priority to JP2024051056A priority Critical patent/JP2024075761A/ja
Application granted granted Critical
Publication of JP7463351B2 publication Critical patent/JP7463351B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514483A 2018-05-16 2019-05-16 脳卒中の血液バイオマーカー Active JP7463351B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024051056A JP2024075761A (ja) 2018-05-16 2024-03-27 脳卒中の血液バイオマーカー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305600.1 2018-05-16
EP18305600 2018-05-16
PCT/EP2019/062653 WO2019219831A1 (en) 2018-05-16 2019-05-16 Blood biomarkers of stroke

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024051056A Division JP2024075761A (ja) 2018-05-16 2024-03-27 脳卒中の血液バイオマーカー

Publications (3)

Publication Number Publication Date
JP2021523744A JP2021523744A (ja) 2021-09-09
JP2021523744A5 true JP2021523744A5 (enExample) 2022-05-23
JP7463351B2 JP7463351B2 (ja) 2024-04-08

Family

ID=62386311

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021514483A Active JP7463351B2 (ja) 2018-05-16 2019-05-16 脳卒中の血液バイオマーカー
JP2024051056A Pending JP2024075761A (ja) 2018-05-16 2024-03-27 脳卒中の血液バイオマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024051056A Pending JP2024075761A (ja) 2018-05-16 2024-03-27 脳卒中の血液バイオマーカー

Country Status (13)

Country Link
US (1) US12247257B2 (enExample)
EP (1) EP3794355A1 (enExample)
JP (2) JP7463351B2 (enExample)
KR (1) KR20210049026A (enExample)
CN (1) CN112424609A (enExample)
AU (1) AU2019270404B2 (enExample)
BR (1) BR112020023259A2 (enExample)
CA (1) CA3100171A1 (enExample)
IL (1) IL278666B2 (enExample)
MA (1) MA52617A (enExample)
MX (1) MX2020012297A (enExample)
SG (1) SG11202011369VA (enExample)
WO (1) WO2019219831A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220093267A1 (en) * 2019-01-22 2022-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Noninvasive real-time patient-specific assessment of stroke severity
CN114107487B (zh) * 2021-12-23 2024-01-09 太原市精神病医院 一种可用于诊断脑卒中的产品
CN116705296B (zh) * 2023-06-06 2024-09-13 中国科学院深圳先进技术研究院 一种基于常规mri序列对gbm患者进行风险分层的方法及系统
WO2025151599A1 (en) * 2024-01-09 2025-07-17 Morehouse School Of Medicine Rna-based method for stroke assessment and treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
WO2003008647A2 (en) * 2000-11-28 2003-01-30 University Of Cincinnati Blood assessment of injury
US9005891B2 (en) 2009-11-10 2015-04-14 Genomic Health, Inc. Methods for depleting RNA from nucleic acid samples
WO2013103781A1 (en) 2012-01-07 2013-07-11 The Regents Of The University Of California Biomarkers for diagnosing ischemia
WO2014052461A1 (en) * 2012-09-25 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Treatment of central nervous system (cns) injury
CN105026579A (zh) 2013-02-01 2015-11-04 西弗吉尼亚大学 用于测定中风症状发作的时间的生物标志物算法以及方法
US11021750B2 (en) 2013-10-13 2021-06-01 The Research Foundation For State University Of Newyork Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof
CA2992139A1 (en) * 2015-07-10 2017-01-19 West Virginia University Markers of stroke and stroke severity
EP3520115A4 (en) 2016-10-03 2020-09-16 West Virginia University RESEARCH IMPLEMENTED BY COMPUTER OF BIOMARKERS OF THE INTERRUPTION OF THE HEMATOENCEPHALIC BARRIER

Similar Documents

Publication Publication Date Title
Robertson et al. Risk stratification in acute variceal bleeding: Comparison of the AIMS65 score to established upper gastrointestinal bleeding and liver disease severity risk stratification scoring systems in predicting mortality and rebleeding
Christ‐Crain et al. Use of B‐type natriuretic peptide in the risk stratification of community‐acquired pneumonia
Schwabl et al. Interferon‐free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease
Zheng et al. Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension
IL278666B2 (en) Blood biomarkers of stroke
RU2016137685A (ru) Способ диагностики туберкулеза
Pronschinske et al. Neutrophil gelatinase-associated lipocalin and cystatin C for the prediction of clinical events in patients with advanced heart failure and after ventricular assist device placement
Taneja et al. Inhibitory control test for the detection of minimal hepatic encephalopathy in patients with cirrhosis of liver
RAHIMI et al. Model for End stage Liver Disease (MELD) and Child-Turcotte-Pugh (CTP) scores: Ability to predict mortality and removal from liver transplantation waiting list due to poor medical conditions
Sinha et al. Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson's disease patients: a proteomic approach
JP2020514689A5 (enExample)
RU2019103403A (ru) Адреномедуллин для оценки застоя у индивидуума с острой сердечной недостаточностью
JP2021523379A5 (enExample)
Bustamante et al. Sepsis biomarkers reprofiling to predict stroke-associated infections
Sawicki et al. Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes
Langsford et al. The association between biomarker profiles, etiology of chronic kidney disease, and mortality
Maznyczka et al. Troponins and other biomarkers in the early diagnosis of acute myocardial infarction
Nishikawa et al. Proposal of a predictive model for advanced fibrosis containing Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein in chronic hepatitis C
Bonanad et al. Serum heat shock protein 60 in acute heart failure: a new biomarker?
Barba et al. Prognostic serum biomarkers of synaptic, neuronal and glial injury in patients with acute ischemic stroke of the anterior circulation
WANG et al. Efficacy of transient elastography in screening for large esophageal varices in patients with suspicious or proven liver cirrhosis
Lim et al. Plasma neutrophil gelatinase-associated lipocalin and kidney function decline and kidney disease-related clinical events in older women
ES2977423T3 (es) Angiopoyetina-2 (Ang-2) circulante y proteína de unión al factor de crecimiento insulínico 7 (IGFBP7) para la predicción de apoplejía
Kube et al. The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure
JP2023548110A5 (enExample)